Nanotechnology for protein delivery: Overview and perspectives

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 24-37

  Yu, Mikyung ^a   Wu, Jun ^a   Shi, Jinjun ^a   Farokhzad, Omid C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Nanoparticle; Nanotechnology; Non invasive administration; Protein delivery; Therapy

Indexed keywords

BIOACTIVITY; MEDICAL APPLICATIONS; NANOPARTICLES; NANOTECHNOLOGY;

ENZYMATIC DEGRADATION; MEMBRANE PERMEABILITY; PROTEIN BASED THERAPEUTICS; PROTEIN DELIVERY; PROTEIN THERAPEUTICS; THERAPEUTIC OUTCOMES; THERAPY; VULNERABLE STRUCTURES;

PROTEINS;

PROTEIN; NANOPARTICLE;

ARTICLE; CHEMICAL MODIFICATION; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; HUMAN; NANOTECHNOLOGY; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; PHYSIOLOGY; PROCEDURES; TISSUE DISTRIBUTION; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PROTEINS; TISSUE DISTRIBUTION;

EID: 84953306043     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.10.012     Document Type: Article

References (139)

1. [1] Leader, B., Baca, Q.J., Golan, D.E., Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7 (2008), 21–39.
2. [2] Leavy, O., Therapeutic antibodies: past, present and future. Nat. Rev. Immunol., 10, 2010, 297.
3. [3] Domling, A., Holak, T.A., Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew. Chem. Int. Ed. 53 (2014), 2–5.
4. [4] Global markets for bioengineered protein drugs. (http://www.reportlinker.com/p02354690-summary/Global-Markets-for-Bioengineered-Protein-Drugs.html), 2014, BBC Research.
5. [5] Haschek, W.M., Rousseaux, C.G., Wallig, M.A., Haschek and Rousseaux's Handbook Of Toxicologic Pathology. third ed., 2013, Elsevier Inc.
6. [6] Shi, J., Xiao, Z., Kamaly, N., Farokhzad, O.C., Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res. 44 (2011), 1123–1134.
7. [7] Kamaly, N., Xiao, Z., Valencia, P.M., Radovic-Moreno, A.F., Farokhzad, O.C., Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41 (2012), 2971–3010.
8. [8] Zhang, L., Gu, F.X., Chan, J.M., Wang, A.Z., Langer, R.S., et al. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83 (2008), 761–779.
9. [9] Etheridge, M.L., Campbell, S.A., Erdman, A.G., Haynes, C.L., Wolf, S.M., McCullough, J., The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9 (2013), 1–14.
10. [10] Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007), 751–760.
11. [11] Sinha, V.R., Trehan, A., Biodegradable microspheres for protein delivery. J. Control. Release 90 (2003), 261–280.
12. [12] Chiellini, F., Piras, A.M., Errico, C., Chiellini, E., Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine 3 (2008), 367–393.
13. [13] Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., Aminabhavi, T.M., Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control. Release 125 (2008), 193–209.
14. [14] Patel, Z.S., Yamamoto, M., Ueda, H., Tabata, Y., Mikos, A.G., Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2. Acta Biomater. 4 (2008), 1126–1138.
15. [15] Builders, P.F., Kunle, O.O., Okpaku, L.C., Builders, M.I., Attama, A.A., Adikwu, M.U., Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin. Eur. J. Pharm. Biopharm. 70 (2008), 777–783.
16. [16] Han, K., Lee, K.D., Gao, Z.G., Park, J.S., Preparation and evaluation of poly(L-lactic acid) microspheres containing rhEGF for chronic gastric ulcer healing. J. Control. Release 75 (2001), 259–269.
17. [17] Morlock, M., Kissel, T., Li, Y.X., Koll, H., Winter, G., Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in-vitro release properties. J. Control. Release 56 (1998), 105–115.
18. [18] Sassi, A.B., Nagarkar, R., Hamblin, P., Novel approaches and strategies for biologics. Singh, M., Salnikova, M., (eds.) Vaccines and Cancer Therapies, 2015, Elsevier Inc, 199–217.
19. [19] Burnham, N.L., Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51 (1994), 210–218.
20. [20] Garnock-Jones, K.P., Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs 75 (2015), 419–425.
21. [21] Moremen, K.W., Tiemeyer, M., Nairn, A.V., Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell. Biol. 13 (2012), 448–462.
22. [22] Deepagan, V.G., Thambi, T., Ko, H., Kang, Y.M., Park, J.H., Amphiphilic polysialic acid derivatives: synthesis, characterization, and in-vitro cytotoxicity. J. Nanosci. Nanotechnol. 13 (2013), 7312–7318.
23. [23] Pisal, D.S., Kosolski, M.P., Balu-Iyer, S.V., Delivery of therapeutic proteins. J. Pharm. Sci. 99 (2010), 2557–2575.
24. [24] Kochendoerfer, G.G., Chen, S.Y., Mao, F., Cressman, S., Traviglia, S., Shao, H., et al. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 299 (2003), 884–887.
25. [25] Nischan, N., Hackenberger, C.P., Site-specific PEGylation of proteins: recent developments. J. Org. Chem. 79 (2014), 10727–10733.
26. [26] Sockolosky, J.T., Szoka, F.C., The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv. Drug Deliv. Rev., 2015 [Epub ahead of print].
27. [27] Challa, D.K., Velmurugan, R., Ober, R.J., Sally Ward, E., FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Curr. Top. Microbiol. Immunol. 382 (2014), 249–272.
28. [28] Czajkowsky, D.M., Hu, J., Shao, Z., Pleass, R.J., Fc-fusion proteins: new developments and future perspectives. EMBO. Mol. Med. 4 (2012), 1015–1028.
29. [29] Fast, J.L., Cordes, A.A., Carpenter, J.F., Randolph, T.W., Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability. Biochemistry 48 (2009), 11724–11736.
30. [30] Bitonti, A.J., Dumont, J.A., Low, S.C., Peters, R.T., Kropp, K.E., et al. Pulmonary delivery of an erythropoietin Fc fusion protein in nonhuman primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. 101 (2004), 9763–9768.
31. [31] Jung, K., Lee, J.E., Kim, H.Z., Kim, H.M., Park, B.S., Hwang, S.I., et al. Toll-like receptor 4 decoy, TOY, attenuates Gram-negative bacterial sepsis. PLoS ONE, 4, 2009, e7403.
32. [32] Muda, M., Gross, A.W., Dawson, J.P., He, C., Kurosawa, E., et al. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng. Des. Sel. 24 (2011), 447–454.
33. [33] Bakema, J.E., Ganzevles, S.H., Fluitsma, D.M., Schilham, M.W., Beelen, R.H., et al. Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy. J. Immunol. 187 (2011), 726–732.
34. [34] Karagiannis, S.N., Josephs, D.H., Karagiannis, P., Gilbert, A.E., Saul, L., et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol. Immunother. 61 (2012), 1547–1564.
35. [35] Ammann, J.U., Jahnke, M., Dyson, M.R., Kaufman, J., Trowsdale, J., Detection of weak receptor–ligand interactions using IgM and J-chain-based fusion proteins. Eur. J. Immunol. 42 (2012), 1354–1356.
36. [36] Levin, D., Golding, B., Strome, S.E., Sauna, Z.E., Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol. 33 (2015), 27–34.
37. [37] Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., Albiglutide Study Group, Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32 (2009), 1880–1886.
38. [38] Schellenberger, V., Wang, C.W., Geething, N.C., Spink, B.J., Campbell, A., To, W., et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27 (2009), 1186–1190.
39. [39] Mitragotri, S., Burke, P.A., Langer, R., Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13 (2014), 655–672.
40. [40] Mellert, K., Lamla, M., Scheffzek, K., Wittig, R., Kaufmann, D., Enhancing endosomal escape of transduced proteins by photochemical internalization. PLoS ONE, 7, 2012, e52473.
41. [41] Vivès, E., Schmidt, J., Pèlegrin, A., Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta 1786 (2008), 126–138.
42. [42] Jo, J., Hong, S., Choi, W.Y., Lee, D.R., Cell-penetrating peptide (CPP)-conjugated proteins is an efficient tool for manipulation of human mesenchymalstromal cells. Sci. Rep., 4, 2014, 4378.
43. [43] Patel, L.N., Zaro, J.L., Shen, W.C., Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res. 24 (2007), 1977–1992.
44. [44] Green, I., Christison, R., Voyce, C.J., Bundell, K.R., Lindsay, M.A., Protein transduction domains: are they delivering?. Trends Pharmacol. Sci. 24 (2003), 213–215.
45. [45] Munyendo, W.L., Lv, H., Benza-Ingoula, H., Baraza, L.D., Zhou, J., Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules 2 (2012), 187–202.
46. [46] Miyaji, Y., Walter, S., Chen, L., Kurihara, A., Ishizuka, T., Saito, M., et al. Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab. Dispos. 39 (2011), 1946–1953.
47. [47] Ramqvist, T., Andreasson, K., Dalianis, T., Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert. Opin. Biol. Ther. 7 (2007), 997–1007.
48. [48] Jennings, G.T., Bachmann, M.F., The coming of age of virus-like particle vaccines. Biol. Chem. 389 (2008), 521–536.
49. [49] Muratori, C., Bona, R., Federico, M., Lentivirus-based virus-like particles as a new protein delivery tool. Methods Mol. Biol. 614 (2010), 111–124.
50. [50] Kaczmarczyk, S.J., Sitaraman, K., Young, H.A., Hughes, S.H., Chatterjee, D.K., Protein delivery using engineered virus-like particles. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 16998–17003.
51. [51] Gaj, T., Guo, J., Kato, Y., Sirk, S.J., Barbas, C.F., Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods 9 (2012), 805–807.
52. [52] Gaj, T., Liu, J., Anderson, K.E., Sirk, S.J., Barbas, C.F. 3rd, Protein delivery using Cys2-His2 zinc-finger domains. ACS Chem. Biol. 9 (2014), 1662–1667.
53. [53] Weeks, B.S., Lieberman, D.M., Johnson, B., Roque, E., Green, M., Loewenstein, P., et al. Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49–58 basic domain. J. Neurosci. Res. 42 (1995), 34–40.
54. [54] Gref, R., Minamitake, Y., Peracchia, M.T., Trubetskoy, V., Torchilin, V., Langer, R., Biodegradable long-circulating polymeric nano-spheres. Science 263 (1994), 1600–1603.
55. [55] Yu, M.K., Park, J., Jon, S., Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2 (2012), 3–44.
56. [56] Hu, C.M., Fang, R.H., Luk, B.T., Zhang, L., Nanoparticle-detained toxins for safe and effective vaccination. Nat. Nanotechnol. 8 (2013), 933–938.
57. [57] Rodriguez, P.L., Harada, T., Christian, D.A., Pantano, D.A., Tsai, R.K., et al. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339 (2013), 971–975.
58. [58] Arruebo, M., Fernández-Pacheco, R., Ibarra, M.R., Santamaría, J., Magnetic nanoparticles for drug delivery. Nano Today 2 (2007), 22–32.
59. [59] Vonarbourg, A., Passirani, C., Saulnier, P., Benoit, J.P., Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27 (2006), 4356–4373.
60. [60] Yu, M.K., Park, J., Jon, S., Magnetic nanoparticles and their applications in image-guided drug delivery. Drug Deliv. Transl. Res. 2 (2012), 3–21.
61. [61] Salvador-Morales, C., Zhang, L., Langer, R., Farokhzad, O.C., Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30 (2009), 2231–2240.
62. [62] Byrne, J.D., Betancourt, T., Brannon-Peppas, L., Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60 (2008), 1615–1626.
63. [63] Lobatto, M.E., Fuster, V., Fayad, Z.A., Mulder, W.J., Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 10 (2011), 835–852.
64. [64] Flogel, U., Ding, Z., Hardung, H., Jander, S., Reichmann, G., In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 118 (2008), 140–148.
65. [65] Chauhan, V.P., Jain, R.K., Strategies for advancing cancer nanomedicine. Nat. Mater. 12 (2013), 958–962.
66. [66] Chauhan, V.P., Stylianopoulos, T., Martin, J.D., Popović, Z., Chen, O., Kamoun, W.S., et al. Normalization of tumor blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7 (2012), 383–388.
67. [67] Choi, H.S., Liu, W., Liu, F., Nasr, K., Misra, P., et al. Design considerations for tumor-targeted nanoparticles. Nat. Nanotechnol. 5 (2010), 42–47.
68. [68] Li, S.D., Huang, L., Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5 (2008), 496–504.
69. [69] Goel, S., Duda, D.G., Xu, L., Munn, L.L., Boucher, Y., Fukumura, D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91 (2011), 1071–1121.
70. [70] Jain, R.K., Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31 (2013), 2205–2218.
71. [71] Batchelor, T.T., Gerstner, E.R., Emblem, K.E., Duda, D.G., Kalpathy-Cramer, J., Snuderl, M., et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 19059–19064.
72. [72] Park, J.H., Von Maltzahn, G., Zhang, L., Schwartz, M.P., Ruoslahti, E., et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20 (2008), 1630–1635.
73. [73] Wohlfart, S., Gelperina, S., Kreuter, J., Transport of drugs across the blood–brain barrier by nanoparticles. J. Control. Release 161 (2012), 264–273.
74. [74] Wang, M., Thanou, M., Targeting nanoparticles to cancer. Pharmacol. Res. 62 (2010), 90–99.
75. [75] Gu, F., Zhang, L., Teply, B.A., Mann, N., Wang, A., Radovic-Moreno, A.F., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 2586–2591.
76. [76] Xiao, C., Ding, J., Ma, L., Yang, C., Zhuang, X., et al. Synthesis of thermal and oxidation dual responsive polymers for reactive oxygen species (ROS)-triggered drug release. Polym. Chem. 6 (2015), 738–747.
77. [77] Uhrich, K.E., Cannizzaro, S.M., Langer, R.S., Shakesheff, K.M., Polymeric systems for controlled drug release. Chem. Rev. 99 (1999), 3181–3198.
78. [78] Kabanov, A.V., Vinogradov, S.V., Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew. Chem. Int. Ed. 48 (2009), 5418–5429.
79. [79] Wu, J., Kamaly, N., Shi, J., Zhao, L., Xiao, Z., Hollett, G., et al. Development of multinuclear polymeric nanoparticles as robust protein nanocarriers. Angew. Chem. Int. Ed. Engl. 53 (2014), 8975–8979.
80. [80] Choi, W.I., Kamaly, N., Riol-Blanco, L., Lee, I.H., Wu, J., Swami, A., et al. A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins. Nano Lett. 14 (2014), 6449–6455.
81. [81] Yan, M., Du, J., Gu, Z., Liang, M., Hu, Y., Zhang, W., et al. A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat. Nanotechnol. 5 (2010), 48–53.
82. [82] Gu, Z., Aimetti, A.A., Wang, Q., Dang, T.T., Zhang, Y., Injectable nano-network for glucose-mediated insulin delivery. ACS Nano 7 (2013), 4194–4201.
83. [83] Zhao, M., Hu, B., Gu, Z., Joo, K.I., Wang, P., Tang, Y., Degradable polymeric nanocapsule for efficient intracellular delivery of a high molecular weight tumor-selective protein complex. Nano Today 8 (2013), 11–20.
84. [84] Windisch, M., Wolf, H., Hutter-Paier, B., Wronski, R., The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?. Neurodegener. Dis. 5 (2008), 218–221.
85. [85] Winklhofer, K.F., Tatzelt, J., Haass, C., The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27 (2008), 336–349.
86. [86] Hasadsri, L., Kreuter, J., Hattori, H., Iwasaki, T., George, J.M., Functional protein delivery into neurons using polymeric nanoparticles. J. Biol. Chem. 284 (2009), 6972–6981.
87. [87] Gulyaev, A.E., Gelperina, S.E., Skidan, I.N., Antropov, A.S., Kivman, G.Y., Kreuter, J., Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999), 1564–1569.
88. [88] Méresse, S., Delbart, C., Fruchart, J.C., Cecchelli, R., Low-density lipoprotein receptor on endothelium of brain capillaries. J. Neurochem. 53 (1989), 340–345.
89. [89] Bluestone, J.A., Bour-Jordan, H., Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb. Perspect. Biol., 4, 2012, a007542.
90. [90] Maldonado, R.A., LaMothe, R.A., Ferrari, J.D., Zhang, A.H., Rossi, R.J., Kolte, P.N., et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E156–E165.
91. [91] Irvine, D.J., Swartz, M.A., Szeto, G.L., Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12 (2013), 978–990.
92. [92] Maldonado, R.A., von Andrian, U.H., How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108 (2010), 111–165.
93. [93] Wilson, J.T., Keller, S., Manganiello, M.J., Cheng, C., Lee, C.C., et al. pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 7 (2013), 3912–3925.
94. [94] Estey, T., Kang, J., Schwendeman, S.P., Carpenter, J.F., BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. J. Pharm. Sci. 95 (2006), 1626–1639.
95. [95] Zhou, P., An, T., Zhao, C., Li, Y., Li, R., Yang, R., et al. Lactosylated PLGA nanoparticles containing ϵ-polylysine for the sustained release and liver-targeted delivery of the negatively charged proteins. Int. J. Pharm. 478 (2015), 633–643.
96. [96] Puri, A., Loomis, K., Smith, B., Lee, J.H., Yavlovich, A., Heldman, E., et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 26 (2009), 523–580.
97. [97] Porter, C.J.H., Wasan, K.M., Constantinides, P., Lipid-based systems for the enhanced delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 60 (2008), 615–616.
98. [98] Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005), 145–160.
99. [99] Kim, S.K., Foote, M.B., Huang, L., The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials 33 (2012), 3959–3966.
100. [100] Park, J., Wrzesinski, S.H., Stern, E., Look, M., Criscione, J., Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater. 11 (2012), 895–905.
101. [101] Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480 (2011), 480–489.
102. [102] Palucka, A.K., Banchereau, J., Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12 (2012), 265–277.
103. [103] Yoshizaki, Y., Yuba, E., Sakaguchi, N., Koiwai, K., Harada, A., Kono, K., Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy. Biomaterials 35 (2014), 8186–8196.
104. [104] Wang, M., Alberti, K., Sun, S., Arellano, C.L., Xu, Q., Combinatorially designed lipid-like nanoparticles for intracellular delivery of cytotoxic protein for cancer therapy. Angew. Chem. Int. Ed. Engl. 53 (2014), 2893–2898.
105. [105] Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E.S., Busini, V., Hossain, N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26 (2008), 561–569.
106. [106] Iordanov, M.S., Ryabinina, O.P., Wong, J., Dinh, T.H., Newton, D.L., Rybak, S.M., et al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res. 60 (2000), 1983–1994.
107. [107] Kim, T., Hyeon, T., Applications of inorganic nanoparticles as therapeutic agents. Nanotechnology, 25, 2014, 012001.
108. [108] Chen, Y., Chen, H., Shi, J., In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv. Mater. 25 (2013), 3144–3176.
109. [109] Han, D.H., Na, H.K., Choi, W.H., Lee, J.H., Kim, Y.K., Won, C., et al. Direct cellular delivery of human proteasomes to delay tau aggregation. Nat. Commun., 5, 2014, 5633.
110. [110] Boisselier, E., Astruc, D., Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev. 38 (2009), 1759–1782.
111. [111] Ghosh, P., Yang, X., Arvizo, R., Zhu, Z.J., Agasti, S.S., Mo, Z., et al. Intracellular delivery of a membrane-impermeable enzyme in active form using functionalized gold nanoparticles. J. Am. Chem. Soc. 132 (2010), 2642–2645.
112. [112] Hong, R., Fischer, N.O., Verma, A., Goodman, C.M., Emrick, T., Rotello, V.M., Control of protein structure and function through surface recognition by tailored nanoparticle scaffolds. J. Am. Chem. Soc. 126 (2004), 739–743.
113. [113] Tang, R., Kim, C.S., Solfiell, D.J., Rana, S., Mout, R., Velázquez-Delgado, E.M., et al. Direct delivery of functional proteins and enzymes to the cytosol using nanoparticle-stabilized nanocapsules. ACS Nano 7 (2013), 6667–6673.
114. [114] Kim, J., Cao, L., Shvartsman, D., Silva, E.A., Mooney, D.J., Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett. 11 (2011), 694–700.
115. [115] Jiang, T., Sun, W., Zhu, Q., Burns, N.A., Khan, S.A., et al. Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene. Adv. Mater. 27 (2015), 1021–1028.
116. [116] Zhang, J., Shin, M.C., David, A.E., Zhou, J., Lee, K., He, H., et al. Long-circulating heparin-functionalized magnetic nanoparticles for potential applications as a protein drug delivery platform. Mol. Pharm. 10 (2013), 3892–3902.
117. [117] Veiseh, O., Tang, B.C., Whitehead, K.A., Anderson, D.G., Langer, R., Managing diabetes with nanomedicine: challenges and opportunities. Nat. Rev. Drug Discov. 14 (2015), 45–57.
118. [118] Woitiski, C.B., Carvalho, R.A., Ribeiro, A.J., Neufeld, R.J., Veiga, F., Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 22 (2008), 223–237.
119. [119] Sonaje, K., Chen, Y.J., Chen, H.L., Wey, S.P., Juang, J.H., Nguyen, H.N., et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31 (2010), 3384–3394.
120. [120] Shan, W., Zhu, X., Liu, M., Li, L., Zhong, J., Sun, W., et al. Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano 9 (2015), 2345–2356.
121. [121] Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci. Transl. Med., 5, 2013, 213ra167.
122. [122] Dombu, C.Y., Betbeder, D., Airway delivery of peptides and proteins using nanoparticles. Biomaterials 34 (2013), 516–525.
123. [123] Amidi, M., Mastrobattista, E., Jiskoot, W., Hennink, W.E., Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 62 (2010), 59–82.
124. [124] Edwards, D.A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M.L., et al. Large porous particles for pulmonary drug delivery. Science 276 (1997), 1868–1871.
125. [125] Nochi, T., Yuki, Y., Takahashi, H., Sawada, S., Mejima, M., Kohda, T., et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9 (2010), 572–578.
126. [126] Keijzer, C., Slütter, B., van der Zee, R., Jiskoot, W., van Eden, W., Broere, F., PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS ONE, 6, 2011, e26684.
127. [127] Li, A.V., Moon, J.J., Abraham, W., Suh, H., Elkhader, J., Seidman, M.A., et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Transl. Med., 5, 2013, 204ra130.
128. [128] Thornton, E.E., Looney, M.R., Bose, O., Sen, D., Sheppard, D., Locksley, R., et al. Spatiotemporally separated antigen uptake by alveolar dendritic cells and airway presentation to T cells in the lung. J. Exp. Med. 209 (2012), 1183–1199.
129. [129] Moon, J.J., Suh, H., Bershteyn, A., Stephan, M.T., Liu, H., Huang, B., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10 (2011), 243–251.
130. [130] Prausnitz, M.R., Langer, R., Transdermal drug delivery. Nat. Biotechnol. 26 (2008), 1261–1268.
131. [131] Choi, W.I., Lee, J.H., Kim, J.Y., Kim, J.C., Kim, Y.H., et al. Efficient skin permeation of soluble proteins via flexible and functional nano-carrier. J. Control. Release 157 (2012), 272–278.
132. [132] He, W., Guo, X., Zhang, M., Transdermal permeation enhancement of N-trimethyl chitosan for testosterone. Int. J. Pharm. 356 (2008), 82–87.
133. [133] Nose, K., Pissuwan, D., Goto, M., Katayama, Y., Niidome, T., Gold nanorods in an oil-base formulation for transdermal treatment of type 1 diabetes in mice. Nanoscale 4 (2012), 3776–3780.
134. [134] DeMuth, P.C., Moon, J.J., Suh, H., Hammond, P.T., Irvine, D.J., Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery. ACS Nano 6 (2012), 8041–8051.
135. [135] Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 8260–8265.
136. [136] Bertrand, N., Wu, J., Xu, X., Kamaly, N., Farokhzad, O.C., Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66 (2014), 2–25.
137. [137] Ye, M., Kim, S., Park, K., Isuues in long-term protein delivery using biodegradable microparticles. J. Control. Release 146 (2010), 241–260.
138. [138] Gu, Z., Biswas, A., Zhao, M., Tang, Y., Tailoring nanocarriers for intracellular protein delivery. Chem. Soc. Rev. 40 (2011), 3638–3655.
139. [139] US FDA, Paving the way for Personalized Medicine; FDA's Role in a new era of Medical Product Development, October. 2013.